SunTrust analyst Peter Lawson raised his price target on Clovis to $35 and kept his Buy rating after its Q4 results, saying the management’s presentation also highlighted “rich 2019 of clinical updates” that are “important for expansion into indications beyond ovarian cancer. The analyst notes that his new model aims to capture upcoming data and expansion opportunities such as the expected late 2019 sNDA filing in prostate cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.